Healthcare stocks as a group have not performed on par with broader equities this year. However, that doesn't mean investors ...

It has been about a month since the last earnings report for CRISPR Therapeutics AG (CRSP). Shares have added about 3.3% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

This juicy upside potential comes at a cost.

If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Crispr Therapeutics AG ( ($CRSP) ) has risen by 9.03%. Read on to learn why. Crispr Therapeutics AG has seen its stock price rise by 9.03% over ...

CRISPR Therapeutics recently drew attention as updates highlighted progress in its gene-editing pipeline, including early-stage studies of CTX310, an in vivo therapy designed to lower LDL cholesterol ...

Discover why CLLS is a top speculative Buy, with promising CAR-T therapies, strong big pharma partnerships, and attractive ...

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

India's GenAI infrastructure is being built, but can a public-private partnership outpace the trillion-dollar budgets of US ...

In a report released today, Alec Stranahan from Bank of America Securities maintained a Buy rating on Beam Therapeutics, with a price target of $43.00. Claim 60% off TipRanks Premium for data-backed ...

Exagamglogene autotemcel helped children with beta thalassemia achieve transfusion independence and prevented vaso-occlusive crises among those with sickle cell disease in a pair of phase 3 ...